Xterna
3 known investors
Find your way into Xterna
265 people in our graph share verified history with the Xterna team — schools, employers, funds. One of them is your warm intro.
Adam Shuaibunlockedknows Jessica Corry · together at University of Cambridge (overlapped)
×6knows the team · via University of Cambridge
knows the team · via The Francis Crick Institute
knows the team · via Crick Science Entrepreneur Network (CSEN)
×3knows the team · via The University of Sheffield
Xterna develops xeno nucleic acid (XNA) technology to engineer cell-specific binders aimed at treating diseases currently considered untreatable. The company operates in the biotechnology and therapeutics space.
Founders & leadership
JC
Jessica CorryinCEO and Co-founderJessica Corry is co-founder of Xterna, a biotechnology company developing engineered nucleic acid binders for cell-specific targeting. She previously held postdoctoral and research roles in academic biotechnology, including at the Francis Crick Institute, and has a PhD in biological sciences from the University of Cambridge.
CW
Chris WaninCSO and Co-founder
Investors · 3
Competitors · 9
by search overlapSepterna6 shared keywordsSepterna is a biotechnology company that uses its proprietary Native Complex Platform to discover and develop oral small molecule therapies targeting GPCRs for endocrinology, immunology and inflammation, and metabolic diseases.
InteRNA5 shared keywordsInterna develops a molecular delivery platform that transports large molecule therapeutics such as DNA, RNA, and proteins across cell membranes to treat infectious and non-infectious diseases. The company's molecular nano-motor technology harnesses the cell membrane's electric potential to enable intracellular drug delivery for respiratory and other therapeutic applications.
Externa5 shared keywordsExterna develops biologics using genetic code expansion, a technology aimed at incorporating synthetic amino acids into proteins of any type and size. The company positions its platform for partnerships in protein and biologics development.
Therna5 shared keywordsTherna develops an AI platform that designs and optimizes programmable RNA medicines, including mRNA and antisense oligonucleotide/siRNA therapeutics, using generative AI models informed by proprietary experimental validation data.
Averna Therapeutics4 shared keywordsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Inspirna4 shared keywordsInspirna is a clinical-stage biopharmaceutical company developing novel cancer drugs that target previously undruggable drivers of metastasis using its proprietary miRNA-DRIVEr platform. The company focuses on common cancers with high unmet need through small molecules and biologics.
AllTrna4 shared keywordsAlltrna develops engineered, chemically modified tRNA oligonucleotides as programmable medicines, using proprietary machine learning tools to design tRNA molecules with desired pharmacologic properties. Its initial therapeutic focus is treating nonsense mutations by reading through premature termination codons to restore full-length protein production, addressing a category it calls Stop Codon Disease.
Entrada Therapeutics, Inc.3 shared keywordsEntrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells. Its pipeline spans discovery to clinical-stage treatments for retinal, neuromuscular, and metabolic diseases, including Duchenne muscular dystrophy.
bio3 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Companies competing with Xterna for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Xterna do?
- Xterna develops xeno nucleic acid (XNA) technology to engineer cell-specific binders aimed at treating diseases currently considered untreatable. The company operates in the biotechnology and therapeutics space.
- Who founded Xterna?
- Xterna was founded by Jessica Corry, Chris Wan.
- Who are Xterna's investors?
- Xterna's investors include SciFounders, Reinforced Ventures, BoxOne Ventures.